(Oxford, UK and Philadelphia, USA) – Oxford BioDynamics Limited and Janssen Research & Development, LLC. have signed an agreement for the use of the EpiSwitchTM platform technology in the development of epigenetic cancer biomarkers for circulating tumour cells (CTCs).

The development agreement will focus initially on EpiSwitchTM biomarkers signatures for the non-invasive detection of CTCs for high performance diagnostic and prognostic stratifications in patients with prostate cancer. Christian Hoyer Millar, CEO of Oxford BioDynamics said that “Oxford BioDynamics are delighted to have the opportunity of working with Janssen to accelerate the development of a new treatment for prostate cancer”.